FOR IMMEDIATE RELEASE:

ABMC LAUNCHES ONLINE TRAINING MODULE
Web-Based Certification Program Helps Drug Test Administrators

KINDERHOOK, N.Y. -- Sept. 25, 2002 -- American Bio Medica Corporation (NASDAQ: ABMC) today announced the launch of a progressive online training and certification course designed specifically to help drug testing program administrators further their understanding of ABMC's products.

Training and certification related to the Company's Rapid Drug Screen® and Rapid One® drug tests is currently available, while training and certification for the Company's OralStat6® and Rapid Tec™ series is expected to be available in the near future. The company introduced the project as a service to its customers, and as a result of growing acceptance and use of its on-site drug tests.

The course can be accessed at www.abmc.com/training. Users are asked to register and create a password, which allows anytime access to the training information. The course provides educational information on the products and their applications, and also an online examination. Those who pass the examination receive a manufacturer's certification.

"With the growing acceptance and use of our products we received requests from customers for more readily-accessible information relative to product training," noted ABMC chairman and CEO Gerald Moore. "Because our products are very easy to use, we can leverage our web site to supplement the efforts of ABMC's sales, technical and customer service staff. It is another example of ABMC going an extra step in responding to the needs of the customer."

About American Bio Medica Corporation

American Bio Medica Corporation is a biotechnology company that develops, manufactures and markets inexpensive, accurate, immunoassay diagnostic test kits, including some of the world's most effective on-site drugs of abuse tests. The company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC's Rapid Drug Screen, Rapid One, and Rapid Tec test for the presence or absence of drugs of abuse in urine, while OralStat6 tests for the presence or absence of drugs of abuse in saliva. ABMC was recently listed among the top ten biotechnology companies on the Deloitte & Touche 2001 Technology Fast 500, a ranking of the fastest growing companies in North America.

This release may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, the following: continued acceptance of the Company's products, increased levels of competition in our industry, the acceptance of new products, inherent risks associated with product development and intellectual property rights, the Company's dependence on key personnel, third party sales and suppliers. There can be no assurance that the Company will be successful in addressing such risks and uncertainties. Investors are strongly encouraged to review the section entitled "Risk Factors" in the Company's annual report on Form 10-KSB for the transition period ended December 31, 2001, and quarterly reports on Form 10-QSB on file with the Securities and Exchange Commission for a discussion of risks and uncertainties that could affect operating results and the market price of the Company's common shares.


Contact:
     American Bio Medica Corporation
     Gerald A. Moore, 800/227-1243
     Fax: 518/758-8171
     gerald@americanbiomedica.com
     www.americanbiomedica.com